BioCryst adopts amended By-Laws for DGCL compliance and universal proxy card rules

BIOCRYST PHARMACEUTICALS INC

Updates to align with DGCL Sections 219 and 222 regarding stockholder list and meeting adjournment.
Revisions to stockholder nomination procedures to comply with universal proxy card rules (Rule 14a-19).
Limits stockholder nominee count to number of directors to be elected; clarifies timing for substitute nominations.
Requires soliciting stockholders to use a proxy card color other than white.
Technical and administrative changes also adopted.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

BIOCRYST PHARMACEUTICALS INC: Amended and Restated By-Laws effective January 16, 2024, including updates to align with Delaware law, revisions to stockholder meeting and nomination procedures, universal proxy rules, and technical changes (effective 2024-01-16).

Change: bylaw amendment
Effective: 2024-01-16

Exact text from the filing

On January 16, 2024, the Board of Directors (the “Board”) of BioCryst Pharmaceuticals, Inc. (the “Company” or “BioCryst”) approved and adopted Amended and Restated By-Laws of the Company (as so amended and restated, the “By-Laws”), that became effective immediately.

View on SEC.gov

84 governance changes filed in the last 30 days. Browse all governance changes →

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-24-000297

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.